Penn spinout Carisma Therapeutics, co-founded by Saar Gill, MD, PhD, Associate Professor of Medicine (Hematology-Oncology) at Penn Medicine, and Michael Klichinsky, PharmD, PhD, Chief Scientific Officer of Carisma, has expanded its collaboration with Moderna to develop two chimeric antigen receptor macrophage (CAR-M) targets for autoimmune disease treatment.
Carisma will spearhead the discovery and optimization of development candidates using its CAR-M technology, while Moderna will lead downstream clinical development and commercialization. This partnership aims to create transformative therapies for both cancer and autoimmune diseases, leveraging Carisma’s expertise in myeloid biology and Moderna’s mRNA platform. Read more here.